Signal Transduction and Targeted Therapy (Mar 2021)

Targeting Erbin in B cells for therapy of lung metastasis of colorectal cancer

  • Tong Shen,
  • Jing-Lin Liu,
  • Chu-Yi Wang,
  • Youlutuziayi Rixiati,
  • Shi Li,
  • Ling-Dong Cai,
  • Yuan-Yuan Zhao,
  • Jian-Ming Li

DOI
https://doi.org/10.1038/s41392-021-00501-x
Journal volume & issue
Vol. 6, no. 1
pp. 1 – 18

Abstract

Read online

Abstract The mechanisms and key factors involved in tumor environments for lung metastasis of CRC are still unclear. Here, using clinical samples from lung metastases of CRC patients, we found that intestinal immune network for IgA production was significantly dysregulated in lung metastases of CRC. Single-cell RNA sequencing discovered a subtype of B cells positive for Erbin, one member of the leucine-rich repeat and PDZ domain (LAP) family, was involved in the lung metastases. Erbin deletion in B cells suppressed lung metastasis of CRC in vivo. And, deletion of Erbin in B cells enhanced the killing effects of CD8+ T cells on tumor cells. Mechanistically, Erbin knockout attenuated TGFβ-mediated suppression of migration of CXCR5+ IgA+ cells and STAT6-mediated PD1 expression. Our study uncovered a key role of Erbin in regulating PD1+ IgA+ B cells in lung metastasis of CRC. Targeting Erbin as well as combined use of neutralizing B cells and antibodies neutralizing PD1 suppresses lung metastasis of CRC in mice, suggesting the potential option for treatment of lung metastasis of CRC.